After Democrats unveil drug price negotiation plan, industry blasts it as 'misguided'

Legislation aimed at slashing high U.S. drug coasts could undercut its own goals by depriving drugmakers of incentives for developing blockbuster medicines, plus lower-cost biosimilars and generics, several analysts and industry groups have warned.